Kancera AB (publ) (KAN.ST)

SEK 1.2

(0.33%)

Long Term Debt Summary of Kancera AB (publ)

  • Kancera AB (publ)'s latest annual long term debt in 2023 was - SEK , down 0.0% from previous year.
  • Kancera AB (publ)'s latest quarterly long term debt in 2024 Q2 was - SEK , down 0.0% from previous quarter.
  • Kancera AB (publ) reported annual long term debt of - SEK in 2022, down -100.0% from previous year.
  • Kancera AB (publ) reported annual long term debt of 442 Thousand SEK in 2021, down -54.76% from previous year.
  • Kancera AB (publ) reported quarterly long term debt of - SEK for 2024 Q2, down 0.0% from previous quarter.
  • Kancera AB (publ) reported quarterly long term debt of - SEK for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Kancera AB (publ) (2023 - 2010)

Historical Annual Long Term Debt of Kancera AB (publ) (2023 - 2010)

Year Long Term Debt Long Term Debt Growth
2023 - SEK 0.0%
2022 - SEK -100.0%
2021 442 Thousand SEK -54.76%
2020 977 Thousand SEK 68.74%
2019 579 Thousand SEK -11.6%
2018 655 Thousand SEK -77.77%
2017 2.94 Million SEK 2.94%
2016 2.86 Million SEK 90.8%
2015 1.5 Million SEK 0.0%
2014 1.5 Million SEK 0.0%
2013 1.5 Million SEK -72.92%
2012 5.54 Million SEK -17.82%
2011 6.74 Million SEK 0.0%
2010 - SEK 0.0%

Peer Long Term Debt Comparison of Kancera AB (publ)

Name Long Term Debt Long Term Debt Difference
Alzinova AB (publ) 800 Thousand SEK 100.0%
Amniotics AB (publ) - SEK NaN%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
BioArctic AB (publ) 2.15 Million SEK 100.0%
Calliditas Therapeutics AB (publ) 939.5 Million SEK 100.0%
Genovis AB (publ.) 74.8 Million SEK 100.0%
LIDDS AB (publ) - SEK NaN%
Magle Chemoswed Holding AB (publ) 32.58 Million SEK 100.0%
OncoZenge AB (publ) - SEK NaN%
Saniona AB (publ) 65.23 Million SEK 100.0%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Vicore Pharma Holding AB (publ) - SEK NaN%
AcouSort AB (publ) - SEK NaN%
Active Biotech AB (publ) 3 Million SEK 100.0%
Camurus AB (publ) 13.61 Million SEK 100.0%
Cantargia AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) - SEK NaN%
Guard Therapeutics International AB (publ) - SEK NaN%
Mendus AB (publ) 850 Thousand SEK 100.0%
Karolinska Development AB (publ) - SEK NaN%
Lipum AB (publ) 1.76 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
NextCell Pharma AB - SEK NaN%
Xbrane Biopharma AB (publ) 112.89 Million SEK 100.0%
Xintela AB (publ) - SEK NaN%
Ziccum AB (publ) 286 Thousand SEK 100.0%
Elicera Therapeutics AB (publ) - SEK NaN%
Modus Therapeutics Holding AB (publ) - SEK NaN%
Isofol Medical AB (publ) - SEK NaN%
Xspray Pharma AB (publ) 31.94 Million SEK 100.0%
CombiGene AB (publ) - SEK NaN%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%
Intervacc AB (publ) 142 Thousand SEK 100.0%
Alligator Bioscience AB (publ) 7.51 Million SEK 100.0%
Sprint Bioscience AB (publ) - SEK NaN%
QuiaPEG Pharmaceuticals Holding AB (publ) - SEK NaN%
Corline Biomedical AB - SEK NaN%
IRLAB Therapeutics AB (publ) 24.51 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) - SEK NaN%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Fluicell AB (publ) - SEK NaN%
Biovica International AB (publ) 4.29 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
Abliva AB (publ) 424 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 103.4 Million SEK 100.0%
2cureX AB (publ) - SEK NaN%
I-Tech AB - SEK NaN%
Hansa Biopharma AB (publ) 844.9 Million SEK 100.0%
Cyxone AB (publ) 74 Thousand SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 1.43 Million SEK 100.0%
Biosergen AB - SEK NaN%
Nanologica AB (publ) 136 Thousand SEK 100.0%
SynAct Pharma AB 58 Thousand SEK 100.0%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
BioInvent International AB (publ) 14.53 Million SEK 100.0%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Pila Pharma AB (publ) - SEK NaN%
Ascelia Pharma AB (publ) 176 Thousand SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%